The ART of tumor immune escape

We recently identified the adenosine-5′-diphosphate (ADP)–ribosyltransferase-1 (ART1) as a novel immune checkpoint expressed by cancer cells. ART1 utilizes free nicotinamide adenine dinucleotide (NAD(+)) in the tumor microenvironment (TME) to mono-ADP-ribosylate (MARylate) the P2X7 receptor (P2X7R)...

Descripción completa

Detalles Bibliográficos
Autores principales: Wennerberg, Erik, Mukherjee, Sumit, Sainz, Ricardo M., Stiles, Brendon M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Author’s View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116389/
https://www.ncbi.nlm.nih.gov/pubmed/35602287
http://dx.doi.org/10.1080/2162402X.2022.2076310
_version_ 1784710102683484160
author Wennerberg, Erik
Mukherjee, Sumit
Sainz, Ricardo M.
Stiles, Brendon M.
author_facet Wennerberg, Erik
Mukherjee, Sumit
Sainz, Ricardo M.
Stiles, Brendon M.
author_sort Wennerberg, Erik
collection PubMed
description We recently identified the adenosine-5′-diphosphate (ADP)–ribosyltransferase-1 (ART1) as a novel immune checkpoint expressed by cancer cells. ART1 utilizes free nicotinamide adenine dinucleotide (NAD(+)) in the tumor microenvironment (TME) to mono-ADP-ribosylate (MARylate) the P2X7 receptor (P2X7R) on CD8 T cells, resulting in NAD-induced cell death (NICD) and tumor immune resistance. This process is blocked by therapeutic antibody targeting of ART1.
format Online
Article
Text
id pubmed-9116389
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Taylor & Francis
record_format MEDLINE/PubMed
spelling pubmed-91163892022-05-19 The ART of tumor immune escape Wennerberg, Erik Mukherjee, Sumit Sainz, Ricardo M. Stiles, Brendon M. Oncoimmunology Author’s View We recently identified the adenosine-5′-diphosphate (ADP)–ribosyltransferase-1 (ART1) as a novel immune checkpoint expressed by cancer cells. ART1 utilizes free nicotinamide adenine dinucleotide (NAD(+)) in the tumor microenvironment (TME) to mono-ADP-ribosylate (MARylate) the P2X7 receptor (P2X7R) on CD8 T cells, resulting in NAD-induced cell death (NICD) and tumor immune resistance. This process is blocked by therapeutic antibody targeting of ART1. Taylor & Francis 2022-05-14 /pmc/articles/PMC9116389/ /pubmed/35602287 http://dx.doi.org/10.1080/2162402X.2022.2076310 Text en © 2022 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Author’s View
Wennerberg, Erik
Mukherjee, Sumit
Sainz, Ricardo M.
Stiles, Brendon M.
The ART of tumor immune escape
title The ART of tumor immune escape
title_full The ART of tumor immune escape
title_fullStr The ART of tumor immune escape
title_full_unstemmed The ART of tumor immune escape
title_short The ART of tumor immune escape
title_sort art of tumor immune escape
topic Author’s View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9116389/
https://www.ncbi.nlm.nih.gov/pubmed/35602287
http://dx.doi.org/10.1080/2162402X.2022.2076310
work_keys_str_mv AT wennerbergerik theartoftumorimmuneescape
AT mukherjeesumit theartoftumorimmuneescape
AT sainzricardom theartoftumorimmuneescape
AT stilesbrendonm theartoftumorimmuneescape
AT wennerbergerik artoftumorimmuneescape
AT mukherjeesumit artoftumorimmuneescape
AT sainzricardom artoftumorimmuneescape
AT stilesbrendonm artoftumorimmuneescape

Ejemplares similares